Ivarmacitinib ‘promising’ for atopic dermatitis not controlled with topical therapies
Gabrielle M. Grasso , 2025-05-09 15:33:00 This is a phase 3 randomized trial of ivarmacitinib, a JAK inhibitor with selectivity for JAK 1, for adolescents and adults with moderate to severe AD. The study is robust, with 336 participants and found that the ivarmacitinib was more effective than placebo and had a favorable risk profile….